The largest database of trusted experimental protocols

Sirnas

Manufactured by Horizon Discovery
Sourced in United States, United Kingdom

SiRNAs (small interfering RNAs) are synthetic, double-stranded RNA molecules that can be used to silence specific genes in cells. They work by binding to and degrading the target mRNA, preventing the production of the corresponding protein.

Automatically generated - may contain errors

161 protocols using sirnas

1

Silencing of Iron-Sulfur Cluster Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
Scrambled siRNA (5′- GGC CGA UUG UCA AAU AAU U- 3′), siRNAs against FDXR (5′-CAC CUU GAU CCA GCG GAC UUA -3′ and 5′- GCU CAG CAG CAU UGG GUA U -3′), siRNAs against FDX2 (5′- GCU GCA AUA AAU CGA UAA CAC -3′ and 5′- GCU GCC AGA UUG UCU GAC AC -3′) and siRNA against IRP2 (5′- GCA AAC AUG UGU CCG GAA U -3′) were purchased from Dharmacon (Chicago, IL, USA). RNAiMax from Life Technology (Carlsbad, CA, USA) was used for siRNA transfection according to the user manual. Cells were transfected with scrambled or target siRNA at 25 nM for 3 days.
+ Open protocol
+ Expand
2

Screening of Cell Death Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
IMR90 ER:RAS cells in suspension (100 μl) were reverse-transfected with siRNAs (Dharmacon) on a well of a 96-well plate. The suspension media was DMEM supplemented with 10% FBS only. The transfection mix for each sample contained 0.2 μl of DharmaFECT™ 1 (Dharmacon) in 17.4 μl plain DMEM mixed with 3.6 μl siRNA 30 min before to cell seeding. 18 hours after transfection, the media was replaced in fresh complete media. 24 hours after transfection, 50 nM ouabain or vehicle (DMSO) were added. The cells were fixed 72 hours after transfection with 4% PFA (w/v) and stained with DAPI (1 μg/ml) for 15 min as previously described. The following siRNAs were acquired from Dharmacon and used in this study: scrambled siRNAs (D-001210-01 and D-001210-02). siRNAs targeting the following human genes: PMAIP1 (D-005275-07 and D-005275-08), BBC3 (D-004380-05 and D-004380-06), BMF (D-004393-25 and D-004393-26), HRK (D-008216-04 and D-008216-05) and BCL2L11 (D-004383-17 and D-004383-18).
+ Open protocol
+ Expand
3

Assessing Symmetric and Asymmetric Satellite Cell Divisions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single myofibers were isolated from EDL muscles of 6–8 week old mice as previously described (Pasut et al., 2013 (link)). Briefly, EDL muscles were dissected and incubated in DMEM (Gibco) containing 0.2% collagenase I (Worthington) for 1 hour. Myofibers were detached using gentle trituration with a glass pipette and washed several times with DMEM. Myofibers were fixed with 2% PFA for 10 min either immediately after isolation, after 36 hours (to analyze when satellite cells are entering the cell cycle), or 42 hours (to analyze when satellite cells have undergone their first division) in culture. For culturing, myofibers were maintained in DMEM high glucose (Life Technologies) supplemented with 20% fetal bovine serum, 1% chick embryo extract and 2.5 ng/ml bFGF. siRNA transfections were performed at 4h and 16h post-culture using Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s instructions. siRNAs were purchased from Dharmacon (Table S3) and used at a final concentration of 50 nM. For the assessment of symmetric and asymmetric satellite stem cell divisions, EDL myofibers were isolated from 9 Myf5-Cre:R26R-EYFP mice. Fibers from each mouse were subsequently treated with siRNA, and approximately 300 satellite cells from 30–35 myofibers were analyzed per condition.
+ Open protocol
+ Expand
4

Silencing cGAS, GSDMD in hLMVECs

Check if the same lab product or an alternative is used in the 5 most similar protocols
siRNAs targeting human cGAS, GSDMD and a siRNA negative control (non-targeting pool siRNA) were obtained from Dharmacon. Transient transfections of these siRNAs (300 nM) in human lung microvasculae endothelial cells (hLMVECs) were performed with the Amaxa human endothelial nucleofector kit (VPI-1001, Lonza) according to the manufacturer’s instructions. To evaluate the efficiency of protein suppresion, protein expression was examined via immunoblotting in cells 2–3 days after transfection.
+ Open protocol
+ Expand
5

siRNA Knockdown of CEBPA in Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
siRNA transfection of cell lines was carried out using INTERFERin (Polyplus transfection). Cells were transfected using 1.0 μl transfection reagent per 0.02 pmol siRNA, and all siRNAs (GE Dharmacon) were used as a pool of four individual sequences at a combined final concentration of 10 nM (Cat.-No.: D-006422-02/04/05/19 for CEBPA with target sequences CAGAGAGCUCCUUGGUCAA, ACAAGAACAGCAACGAGUA, CGGUGGACAAGAACAGCAA, and GGAACACGAAGCACGAUCA). Luciferase reporter assays were set up as described 48 h after siRNA transfection.
+ Open protocol
+ Expand
6

Transient Knockdown of SET and CIP2A

Check if the same lab product or an alternative is used in the 5 most similar protocols
Transient SET (M-019586-01) and CIP2A (M-014135-00) knockdowns were performed using siRNAs (Dharmacon) and DharmaFECT I transfection reagent. Non-targeting siRNA (D-001206-14) was used as a control. Briefly, cells were plated in 10 cm dishes in antibiotic-free medium and allowed to adhere overnight. 5 μM siRNA stock solution was prepared in water and siRNAs were diluted to a final concentration of 25 nM in 600 μl serum free medium. 12 μl DharmaFECT I was diluted in 588 μl serum-free medium. The siRNA and Dharmafect mixes were then combined, incubated at room temperature for 20 minutes, and added to cells. Cell were incubated with transfection mix for 24 hrs and then cells were seeded for additional experiments.
+ Open protocol
+ Expand
7

Silencing Proteins with siRNA Transfection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Small interfering RNAs (siRNAs; Dharmacon Inc.) were transfected using Lipofectamine RNAi MAX (Invitrogen) as per the manufacturer’s protocol. The final concentration of the siRNA was 40 nM and the cells were lysed 72 h post-transfection. For SET7 siRNA, SMARTpool were purchased from Dharmacon Inc. For FEN1, the sequence of the siRNA used was 5′-GUU CUC UGA GGA GCG AAU C-3′. Luciferase siRNA was used as control.
+ Open protocol
+ Expand
8

siRNA-Mediated Knockdown Experiment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Scrambled siRNA (5′-GCA GUG UCU CCA CGU ACU AdTdT-3′), siRNAs against IRP2 (siIRP2#1:5′-GCG AUU UCC AGG CUU GCU UdTdT −3′ and #2: 5′-GCA AAC AUG UGU CCG GAA dTdT-3′), and siRNA against human TAp63 (5′-GAU GGU GCG ACA AAC AAG AdTdT-3′) were purchased from Dharmacon. For siRNA transfection, RNAiMax Lipid Reagent (Thermo Fisher Scientific) was used according to the manufacturer’s manual. The siRNAs were transfected into the cells at the final concentration of 30 nmol/L for 3 days.
+ Open protocol
+ Expand
9

siRNA Transfection Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were transfected with siRNAs (Dharmacon; Table S4) using DharmaFECT-1 (Dharmacon). In control transfections, siRNA buffer (Dharmacon) was added instead of siRNAs.
+ Open protocol
+ Expand
10

Knockdown of NIPBL, WAPL, and CTCF in HCT-116 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
HCT-116 cells were cultured in McCoy’s 5A medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C with 5% CO2. The following siRNAs (Dharmacon) were used: Non-targeting control, NIPBL, WAPL, CTCF. siRNA sequences can be found in Supplementary Table 2. Duplex siRNA were incubated for 20 minutes at room temperature with RNAiMAX transfection reagent (Thermo Fisher) in Opti-MEM reduced serum medium (Thermo Fisher) and seeded into wells. HCT-116 were trypsinized and resuspended in antibiotic-free medium, then plated with medium containing siRNA for a final siRNA concentration of 50 nM (non-targeting control, NIPBL, or WAPL) or 150 nM (CTCF). For CTCF knockdowns, cells were retreated with 150nM CTCF siRNAs 24 hours after initial treatment. After 72 h (NIPBL, WAPL, non-targeting control) or 96 h from the initial RNAi treatment (CTCF), cells were harvested for experiments. For the CTCF and RAD21 double-knockdown experiments, cells were grown in medium supplemented with 500 μM indole-3-acetic acid (auxin; Sigma-Aldrich I5148) for 6 hours following RNAi treatments, and then harvested for experiments.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!